Gilead Sciences | GILD - DEBITO





DEBITO Cambiamento Data
AbbVie USD 67.5B 67.5B 2025-12
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
ALKERMES USD 1.58B 1.51B 2026-03
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Amgen USD 54.6B 17M 2025-12
Biogen USD 6.56B 275.1M 2026-03
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Coherus Biosciences USD 294.92M 1.25M 2025-03
Eli Lilly USD 42.5B 3.6M 2025-12
Gilead Sciences USD 24.94B 5M 2025-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Glaxosmithkline GBP 19.06B 1.31B 2026-03
Incyte USD 39.43M 982K 2026-03
J&J USD 54.99B 7.05B 2026-03
Merck USD 49.34B 7.97B 2025-12
Moderna USD 1.31B 571M 2025-12
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 47B 11.62B 2026-03
Pfizer USD 63.73B 231M 2026-03
PTC Therapeutics USD 286.94M 2.42B 2026-03
Puma Biotechnology USD 89.06M 55.07M 2024-06
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 20.33B 1.43B 2025-12
Sarepta Therapeutics USD 1.04B 210.44M 2025-12
United Therapeutics USD 200M 100M 2025-03
Vertex Pharmaceuticals USD 1.99B 44M 2026-03